Hitchcock Todd A

EVP/COO Hitchcock Todd A sold 16,500 shares of UTI at $37.33 for $615,945.00 on 2026-03-04; stock at $34.99 now

Hitchcock Todd A, EVP/COO, executed a discretionary open-market sale of 16,500 shares representing -13.7% of pre-transaction holdings, completing the transaction at $37.33, which was near the 52-week high of $37.50. Notably, his prior two sales at UTI (both on 2025-05-15) demonstrated strong 90-day timing, with each followed by negative returns of -22.7% and -23.8%, establishing a pattern of selling ahead of declines. His cross-ticker track record shows a 100.00% well-timed rate across 2 prior open-market sells. The current price of $34.99 represents a -6.7% pullback from the 52-week high and a decline since the transaction date, consistent with his established selling pattern. The company's strong fundamentals (revenue growth of +14.0% annually, net income of $12,827,000.00, and a P/E of 35.70) suggest the timing reflects market positioning rather than fundamental deterioration.

UTI EVP/COO Todd Hitchcock sold 27,500 shares for $917,470.50 on 2025-05-15; reduces holdings by -25.5%

On 2025-05-15, Hitchcock executed 2 separate sales totaling 27,500 shares for $917,470.50 at an average price of $33.36, reducing his stake from 108,021 shares to 80,521 shares. The current stock price of $34.62 sits at the 52-week high with strong recent momentum (+24.8% over 30 days, +21.9% over 90 days). The company shows solid fundamentals with 20.6% annual revenue growth, $207.4M quarterly revenue, and a market cap of $1.9B, though the 32.66 P/E suggests the stock is trading at a premium valuation. The 25.5% reduction in his holdings, executed while the stock trades at its 52-week high, represents a material divestiture by a senior executive.